|Rapid Review Complete
|For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise/as monotherapy when metformin is considered inappropriate due to intolerance or contraindications/in addition to other medicinal products for the treatment of diabetes
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.
The HSE has approved reimbursement September 2018.